Eli Lilly and Company (LLY)vsInnovative Eyewear Inc. (LUCY)
LLY
Eli Lilly and Company
$1,229.16
+1.81%
HEALTHCARE · Cap: $1.08T
LUCY
Innovative Eyewear Inc.
$0.78
+1.05%
HEALTHCARE · Cap: $5.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2423794% more annual revenue ($72.25B vs $2.98M). LLY leads profitability with a 35.0% profit margin vs -272.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
LUCY
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+40.5%
Fair Value
$1.85
Current Price
$0.78
$1.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Revenue surging 70.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 35.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -102.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 70.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.9x leaves little room for execution misses.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while LUCY is a hypergrowth play — different risk/reward profiles.
LUCY carries more volatility with a beta of 2.70 — expect wider price swings.
LUCY is growing revenue faster at 70.2% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 38/100), backed by strong 35.0% margins and 55.5% revenue growth. LUCY offers better value entry with a 40.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) stands at the forefront of the smart eyewear sector, merging advanced technology with appealing aesthetics to meet the needs of modern, tech-savvy consumers. Its flagship product line, Lucyd, is designed to provide integrated audio features and seamless connectivity, offering a blend of convenience and style. Firmly focused on enhancing user experience and driving innovation, LUCY is well-positioned to leverage the growing demand for multifunctional eyewear, creating significant growth opportunities in a rapidly evolving market. As the trend towards smart, connected devices accelerates, LUCY’s strategic initiatives to promote its product offerings place it in a strong position for long-term competitiveness and success.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?